Stephanie Sutton

A class of action has been filed that seeks to prevent Novartis' proposed merger with eye-care company Alcon, which will see Alcon's minority public shareholders "squeezed out at an unfair price", according to a statement from US law firm Labaton Sucharow LLP.

Many life sciences companies are likely to execute an acquisition in the next 12–24 months as economic conditions improve, according to Why capital matters, a global survey of senior executives in the life sciences sector conducted by Ernst & Young in 2009.

The EC has asked certain pharmaceutical companies to submit copies of their patent settlement agreements; in particular, the EC will be looking at settlements where an originator paid off a generic competitor in return for delayed market entry of a generic drug.

Many life-sciences companies are likely to execute an acquisition in the next 12-24 months, according to a survey by Ernst & Young.

The European Commission has asked certain pharmaceutical companies to submit copies of their patent-settlement agreements.

Microelectronics offers "striking opportunities" for advancing biomedical research and creating new markets for the medical sciences industry, according to analysis from Frost & Sullivan.

Influenza vaccines can be produced faster using a new insect cell-based technology compared with traditional egg-based processes, according to scientists in Vienna (Austria).

Influenza vaccines can be produced faster using a new insect cell-based technology compared with traditional egg-based processes, according to scientists in Vienna, Austria.

Microelectronics offers "striking opportunities" for advancing biomedical research and creating new markets for the medical sciences industry.

Pharmaceutical Technology Europe discusses some of the innovations in drug delivery that could shape the future of the pharma market.

Analysis examining voluntary environmental and social reporting for 26 of the world's largest pharmaceutical companies has revealed that many big players, including Pfizer, have room for improvement.

M&As remain an integral part of Big Pharma's strategy and will contribute almost two-thirds of peer set sales growth up to 2014, according to market analyst Datamonitor.

Fraud and abuse in healthcare costs individual governments as much as $23 billion a year, according to estimates from the World Health Organization (WHO).

Analysis examining voluntary environmental and social reporting for 26 of the world's largest pharmaceutical companies has revealed that many big players, including Pfizer, have room for improvement.

Mergers and acquisitions will contribute almost two-thirds of peer-set sales growth until 2014, according to market analyst Datamonitor.

Do advanced therapies represent medical miracles or risky business? This is the question that is debated by an Informa analyst in an Executive Briefing for Scrip.

Personalized medicine has been described by analysts PricewaterhouseCoopers (PwC) as a "disruptive influence" that will create both opportunities and challenges for traditional healthcare.

Personalized medicine has been described by analysts PricewaterhouseCoopers as a "disruptive influence" that will create both opportunities and challenges for traditional healthcare.

The private industry has been urged to join a public sector commitment fund in the UK to advance manufacturing R&D in bioprocessing, following the investment of approximately £9 million from two UK research councils.

Guidance has been published in the UK regarding a new European variations regulation that comes into effect on 1 January 2010.

European business leaders are missing opportunities to reduce their environmental footprint and drive efficiencies through document governance, according to research from Ricoh, an electronic solutions provider.

Guidance has been published in the United Kingdom regarding a new European variations regulation that comes into effect on Jan. 1, 2010.

The end of 2009 is creeping closer and analysts are already looking towards 2010 and wondering what new challenges are in store for the pharma industry.

Five per cent of consumers across five European countries suspect they may have received a counterfeit prescription and 1% believe that they definitely have, according to research conducted by ICM on behalf of patient safety communications company Aegate (UK).

An agreement between sanofi-aventis and the Medicines for Malaria Venture (MMV) has lead to the initiation of the largest safety and efficacy study of an antimalarial drug.

After further reviewing data on the H1N1 pandemic vaccines approved in Europe, the EMEA has reaffirmed their balance of benefits and risks in the context of the current H1N1 influenza pandemic. Additionally, the World Health Organization (WHO) has issued an update on the H1N1 situation in Europe.

Five percent of consumers across five European countries suspect they may have received a counterfeit prescription, and 1% believe that they definitely have, according to research conducted by ICM on behalf of patient safety communications company Aegate (UK).

Engineers at a UK university claim to have developed technology that can be used in existing chemical reactors to ensure right first time drug crystal formation, which is crucial to their efficacy and the efficiency of pharmaceutical manufacturers' operations.

A consortium led by GlaxoSmithKline (UK) intends to deliver a "step change improvement" in pharmaceutical tablet manufacturing in the UK by "substantially" increasing the country's manufacturing efficiency.

A consortium led by GlaxoSmithKline (UK) intends to deliver a "step change improvement" in pharmaceutical tablet manufacturing in the UK by "substantially" increasing the country's manufacturing efficiency.